Nerve growth factor (NGF) plays a central role in multiple chronic pain conditions. As such, anti-NGF monoclonal antibodies (mAbs) that function by antagonizing NGF downstream signaling are leading drug candidates for non-opioid pain relief. To evaluate anti-canine NGF (cNGF) mAbs we sought a yeast surface display platform of cNGF. Both mature cNGF and pro-cNGF displayed on the yeast surface but bound conformationally sensitive mAbs at most 2.5-fold in mean fluorescence intensity above background, suggesting that cNGF was mostly misfolded. To improve the amount of folded, displayed cNGF, we used comprehensive mutagenesis, FACS, and deep sequencing to identify point mutants in the pro-region of canine NGF that properly enhance the folded protein displayed on the yeast surface. Out of 1,737 tested single point mutants in the pro region, 49 increased the amount of NGF recognized by conformationally sensitive mAbs. These gain-of-function mutations cluster around residues A-61-P-26. Gain-of-function mutants were additive, and a construct containing three mutations increased amount of folded cNGF to 23-fold above background. Using this new cNGF construct, fine conformational epitopes for tanezumab and three anti-cNGF mAbs were evaluated. The epitope revealed by the yeast experiments largely overlapped with the tanezumab epitope previously determined by X-ray crystallography. The other mAbs showed site-specific differences with tanezumab. As the number of binding epitopes of functionally neutralizing anti-NGF mAbs on NGF are limited, subtle differences in the individual interacting residues on NGF that bind each mAb contribute to the understanding of each antibody and variations in its neutralizing activity. These results demonstrate the potential of deep sequencing-guided protein engineering to improve the production of folded surface-displayed protein, and the resulting cNGF construct provides a platform to map conformational epitopes for other anti-neurotrophin mAbs.
Submitter: Shu-Ching Ou
Submission Date: July 11, 2018, 11:41 a.m.
|Number of data points||14229|
|Proteins||Pro.v4-cNGF, a conformational epitope mapping of Pro-cNGF ; ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF) ; Pro Canine Nerve growth factor (pro-cNGF) ; Canine Nerve growth factor (cNGF)|
|Assays/Quantities/Protocols||Experimental Assay: cNGF-Tanezumab/mAb#1 enrichment ratios sort 2 ; Experimental Assay: cNGF-Tanezumab/mAb#1 enrichment ratios sort 1 ; Experimental Assay: Pro.v4-Tanezumab/mAbs Binding|
|Libraries||ProcNGF-mAb#1 Enrichment Ratios ; ProcNGF-Tanezumab Enrichment Ratios ; Pro.v4-cNGF-mAb#3 Relative Binding Score ; Pro.v4-cNGF-mAb#2 Relative Binding Score ; Pro.v4-cNGF-mAb#1 Relative Binding Score ; Pro.v4-cNGF-Tanezumab Relative Binding Score ; ProΔ1,2-cNGF-mAb#1 Enrichment Ratios ; ProΔ1,2-cNGF-Tanezumab Enrichment Ratios|
|Percent Identity||Matching Chains||Protein||Accession||Entry Name|
|93.5||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||Q29074||NGF_PIG|
|92.5||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||Q5ISB0||NGF_SAIBB|
|91.0||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||P13600||NGF_BOVIN|
|92.0||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||Q9N2F0||NGF_GORGO|
|92.0||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||Q9N2F1||NGF_PANTR|
|91.5||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||P01138||NGF_HUMAN|
|91.0||ProΔ1,2 canine nerve growth factor (proΔ1,2-cNGF)||Q9N2E9||NGF_PONPY|